Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
NRG Oncology
NRG Oncology
Mayo Clinic
Emory University
University of Utah
Massachusetts General Hospital
Memorial Sloan Kettering Cancer Center
Medical College of Wisconsin
UNICANCER
IRCCS San Raffaele
Thomas Jefferson University
First Hospital of China Medical University
Fundacion IMIM
UNICANCER
Wake Forest University Health Sciences
OHSU Knight Cancer Institute
The Netherlands Cancer Institute
University Hospital Freiburg
University Health Network, Toronto
Centre Georges Francois Leclerc
Samsung Medical Center
University of Nebraska
Emory University
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Georgetown University
Georgetown University
University of California, Davis
University of California, San Francisco
Institut Cancerologie de l'Ouest
University of Texas Southwestern Medical Center
University Hospital, Geneva
Mayo Clinic
Abramson Cancer Center at Penn Medicine
University of Kentucky
University of California, San Francisco
Institut de Cancérologie de Lorraine
University of Kansas Medical Center
AHS Cancer Control Alberta
Benaroya Research Institute
Nova Scotia Cancer Centre
Mayo Clinic